Evidence map›Paper›PMID 26865585›Full record

ArticleEuropean journal of endocrinology2016

Diffuse parathyroid hormone expression in parathyroid tumors argues against important functional tumor subclones.

Felix Haglund, C Christofer Juhlin, Nimrod B Kiss, Catharina Larsson, Inga-Lena Nilsson, Anders Höög

Open access · hybridAbstract read
In one paragraph

Article in European journal of endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Intratumor heterogeneity in human parathyroid tumors.Histology and histopathology · 2020
    Review
  6. Article
  7. Inflammatory infiltrates in parathyroid tumors.European journal of endocrinology · 2017
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Felix HaglundDepartment of Oncology-PathologyKarolinska Institutet, Karolinska University Hospital CCK, SE-171 76 Stockholm, Sweden Felix.Haglund@ki.se.
C Christofer JuhlinDepartment of Oncology-PathologyKarolinska Institutet, Karolinska University Hospital CCK, SE-171 76 Stockholm, Sweden.
Nimrod B KissDepartment of Oncology-PathologyKarolinska Institutet, Karolinska University Hospital CCK, SE-171 76 Stockholm, Sweden.
Catharina LarssonDepartment of Oncology-PathologyKarolinska Institutet, Karolinska University Hospital CCK, SE-171 76 Stockholm, Sweden.
Inga-Lena NilssonDepartment of Molecular Medicine and SurgeryKarolinska Institutet, Karolinska University Hospital CCK, SE-171 76 Stockholm, Sweden.
Anders HöögDepartment of Oncology-PathologyKarolinska Institutet, Karolinska University Hospital CCK, SE-171 76 Stockholm, Sweden.
Karolinska Institutet · SEKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePrimary hyperparathyroidism is usually characterized by a monoclonal parathyroid tumor secreting excess parathyroid hormone (PTH). The main regulator of PTH secretion is calcium and the calcium-PTH set point is shifted in parathyroid tumor cells. We sought to investigate the relationship between tumor PTH and PTH mRNA expression and clinical presentation as well as the regulatory factors including phosphate, vitamin D, and fibroblast growth factor 23.

designA total of 154 parathyroid tumors were analyzed by PTH immunohistochemistry and chromogenic in situ hybridization of PTH mRNA. A subset of samples (n = 34) was analyzed using quantitative real-time PCR.

resultsLow tumor PTH mRNA level was significantly associated with low tumor PTH immunoreactivity (P = 0.026), but the two did not correlate with regard to histological distribution within individual tumors. Tumors displaying reduced PTH mRNA levels as compared with normal rim were significantly larger (P = 0.013) and showed higher expression of the calcium-sensing receptor (CASR) (P = 0.046). Weaker tumor PTH mRNA level was significantly associated with higher concentration of circulating 25-hydroxyvitamin D (P = 0.005). No significant correlation was seen between PTH immunoreactivity and patient biochemistry. Tumor weight was strongly associated with circulatory concentrations of calcium and PTH.

conclusionsNo areas with apparently higher PTH expression were identified, perhaps suggesting that hyper functioning parathyroid tumor subclones should be rare. Circulating 25-hydroxyvitamin D levels may influence tumor PTH expression in vivo. If PTH immunoreactivity reflects the tumor calcium-PTH set point, our data imply that the main determinant of disease severity should be tumor weight.

Indexed as

AdenomaCalciumCohort StudiesGene ExpressionHumansImmunohistochemistryIn Situ HybridizationParathyroid HormoneParathyroid NeoplasmsReal-Time Polymerase Chain ReactionRNA, MessengerVitamin D25-hydroxyvitamin DCalciumParathyroid HormoneRNA, MessengerVitamin D

Identifiers

PMID26865585
PMCPMC5081673
OpenAlexW2258669446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.